Myriam Hakim outlines the progress that Japanese rare disease and oncology specialist Kyowa Kirin has made in the GCC region in recent years; the…

A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…

Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…

COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than…

The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their…

Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the…

Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most…

In some respects, is it perhaps the medtech sector that has most to be excited about in the UAE’s domestic market, given the country’s unrelenting…

The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the country out as worthy of attention as…

Myriam Hakim, the recently appointed GM for Japanese specialty pharma firm Kyowa Kirin’s UAE affiliate, discusses the strategic significance of the…